G&E Herbal Biotechnology Cash Flow Statement

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Net Income	139.2	102.06	72.4	7.38	-19.88
Depreciation & Amortization	10.61	10.38	9.33	9.4	9.33
Other Amortization	-	-	-	-	0
Loss (Gain) From Sale of Assets	0.03	0.01	0.01	0	0.02
Other Operating Activities	12.32	22.5	17.98	0.71	1.67
Change in Accounts Receivable	0.74	-3.04	-14.19	4.38	1.08
Change in Inventory	-3.59	1.2	1.74	-5.69	-2.85
Change in Accounts Payable	-0.55	1.42	-2	2.47	-0.35
Change in Unearned Revenue	-85.1	-10.01	23.39	71.39	0.28
Change in Other Net Operating Assets	-3.49	10.16	4.82	9.92	1.52
Operating Cash Flow	70.18	134.68	113.48	99.96	-9.19
Operating Cash Flow Growth	-47.89%	18.68%	13.52%	-	-
Capital Expenditures	-3.2	-5.92	-5.52	-2.95	-1.77
Sale (Purchase) of Intangibles	-	-0.08	-	-0.01	-0.22
Investment in Securities	-95.61	-83.05	-82.04	5.4	9
Other Investing Activities	-	-0.19	-0.87	0.07	-
Investing Cash Flow	-98.82	-89.24	-88.43	2.51	7.01
Long-Term Debt Repaid	-0.88	-0.77	-0.12	-	-
Net Debt Issued (Repaid)	-0.88	-0.77	-0.12	-	-
Common Dividends Paid	-44.66	-31.76	-	-	-
Financing Cash Flow	-45.53	-32.54	-0.12	-	-
Net Cash Flow	-74.17	12.9	24.94	102.47	-2.18
Free Cash Flow	66.98	128.76	107.96	97.01	-10.96
Free Cash Flow Growth	-47.98%	19.26%	11.29%	-	-
Free Cash Flow Margin	21.67%	51.70%	59.50%	150.15%	-44.61%
Free Cash Flow Per Share	1.05	2.02	1.69	1.52	-0.17
Cash Interest Paid	0.03	0.04	0	-	-
Cash Income Tax Paid	6.77	0.15	0.02	-	-
Levered Free Cash Flow	22.62	82.35	67.88	93.19	-5.52
Unlevered Free Cash Flow	22.64	82.37	67.88	93.19	-5.52
Change in Working Capital	-91.98	-0.28	13.76	82.47	-0.32

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.